It has not been a good day for investors this Thursday.  Worries about trade, the situation in Saudi Arabia, plunging oil prices, falling …

EyePoint Pharmaceuticals (EYPT) has a big reason to celebrate this week — the Food and Drug Administration (FDA) approved the vision-improving technology. The fluocinolone …

Oppenheimer analyst Leland Gershell was out pounding the table on shares of Catalyst Pharmaceuticals (CPRX), reiterating a Buy rating and price target of $6.00, which implies …

It’s one small step forward for Vascular Biogenics (VBLT), one giant leap for the company’s stock rating. H.

Drug company AcelRx (ACRX) is likely celebrating its first win after getting news from the Food and Drug Administration (FDA) late Friday afternoon …

Investors have been treated like rented mules by the market so far here in October.  More than 75% of the S&P 500 (including …

Investors are jumping in and out ahead of a Food and Drug Administration (FDA) decision on AcelRx’s (ACRX) opioid pain drug Dsuvia, with …

Acelrx’s (ACRX) shares popped over 20% in pre-market trading Monday, following indications that the U.S.

Some investors might love biotech stocks for their lottery ticket-like returns when a company wins the regulator’s blessing. A lottery ticket, however, costs only …

In a research note issued today, healthcare analyst Alan Carr of Needham walks investors through this week’s Trevena (TRVN) bloodbath. Shares are down nearly over …